Cafergot pairs ergotamine tartrate with caffeine to abort acute migraine attacks when taken promptly at the earliest signs. Ergotamine is an ergot alkaloid that narrows dilated cranial blood vessels and modulates trigeminal neurotransmission implicated in migraine pain. Caffeine complements this action by improving the gastrointestinal absorption of ergotamine, speeding onset, and exerting additional vasoconstrictive and adenosine-receptor–mediated effects that can blunt migraine pathways. The combination is most effective when used during the prodrome or aura, or at the very start of head pain, before central sensitization fully develops.
Clinically, patients may experience a shortened attack duration, decreased pain intensity, and reduced associated symptoms such as photophobia and phonophobia. Cafergot is not a preventive medicine; it should not be taken daily or on a schedule between attacks. It is generally considered for people who cannot tolerate triptans, did not respond adequately to them, or for whom other acute options (such as gepants or a ditan) are not suitable. In select cases, some clinicians also consider ergotamine-containing products for cluster headaches; this must be individualized and carefully supervised.
Because ergotamine strongly constricts blood vessels, the medicine is inappropriate for patients with cardiovascular or peripheral vascular disease and must be used judiciously in anyone with risk factors for ischemia. Your clinician will help you weigh benefits versus risks and determine whether Cafergot fits into your broader migraine treatment plan, which may also include preventive therapies, trigger management, hydration strategies, sleep hygiene, and non-drug interventions.
Use Cafergot exactly as prescribed. Timing and dose limits are critical to both effectiveness and safety.
Taking Cafergot with food can lessen stomach upset, though a small snack is sufficient. If nausea is prominent during your attacks, your clinician may recommend an antiemetic (for example, metoclopramide or prochlorperazine) to take before or with your first Cafergot dose. Swallow tablets whole; do not crush or chew.
Do not take Cafergot within 24 hours before or after using a triptan (such as sumatriptan, rizatriptan, or eletriptan). Avoid combining with other ergot-containing medications or potent vasoconstrictors. If your headache has already escalated to severe intensity or has persisted for many hours before your first dose, Cafergot may be less effective; discuss backup options (such as a gepant, a ditan, or a clinic-administered rescue plan) with your clinician.
Special considerations:
Because ergotamine-caffeine has a narrow therapeutic window, prudent screening and counseling are essential. Before your first prescription and each refill, speak with a healthcare professional about the following safety checks:
Warning signs that require immediate medical care include chest pain, sudden shortness of breath, severe abdominal pain, fainting, one-sided weakness or numbness, slurred speech, new vision loss, or cold, painful, blue, or numb fingers and toes. Stop Cafergot and seek emergency care if any of these occur.
Do not use Cafergot if any of the following apply:
Use is also not recommended for basilar-type or hemiplegic migraine because of the elevated risk of vascular complications in these subtypes. Children and adolescents generally should not use ergotamine-containing products unless specifically advised by a specialist.
Most side effects are dose-related and improve as the medication wears off. Understanding what is common versus concerning helps you use Cafergot more confidently and safely.
Common side effects:
Less common but serious effects that require urgent care:
Overuse risks: Using Cafergot too frequently can cause medication-overuse headache (rebound), characterized by near-daily or daily headaches that improve when ergotamine is discontinued. Additionally, cumulative exposure may precipitate ergotism, a rare but serious syndrome of intense vasoconstriction leading to limb pain, numbness, cyanosis, and tissue injury. Adhere strictly to the dosing limits and weekly caps to minimize these risks.
If side effects are troublesome, consult your clinician. Adjusting timing, lowering the number of repeat doses, adding an antiemetic, or switching to an alternative acute therapy (such as a gepant or a ditan) may improve tolerability and outcomes.
Ergotamine is metabolized primarily via CYP3A4. Medicines that inhibit this enzyme can dramatically elevate ergotamine levels, increasing the risk of severe vasospasm and ischemic complications. Always review your full medication list with your clinician and pharmacist before you start Cafergot or buy it online.
Avoid the following unless specifically cleared by your prescriber:
Additional notes:
Cafergot is not taken on a schedule. If you did not take it at the onset of migraine, you may still take it once symptoms begin, staying within the single-attack and weekly dose limits. Do not double doses to “catch up,” and never use it between attacks as a preventive strategy. If you are consistently missing the optimal timing window, talk with your clinician about early-treatment cues, adding an antiemetic, or selecting a different acute therapy that better matches your attack pattern.
Overdose, drug interactions, or unusual sensitivity can produce life-threatening toxicity. Warning signs include intense or persistent nausea/vomiting, confusion, extremely high or low heart rate, chest pain, severe hypertension, cold/painful limbs, numbness or weakness, vision changes, or seizures. If you suspect an overdose or serious reaction:
Protect the medicine to preserve potency and reduce accidental exposure.
Travel tip: Keep Cafergot in its original labeled container in your carry-on bag to avoid heat extremes and ensure availability if a migraine begins during transit.
In the United States, Cafergot is a prescription-only medication. Any legitimate online pharmacy will require a valid prescription issued after a proper medical evaluation by a licensed clinician. You can obtain that evaluation through your own provider, an independent telehealth prescriber, or a compliant service connected with HealthSouth Rehabilitation Hospital of Montgomery. Reputable pharmacies will not ship Cafergot without a prescription.
How to buy Cafergot online safely:
Insurance, pricing, and refills:
Small adjustments can improve effectiveness while minimizing risk.
Choosing an acute therapy depends on your health profile, previous responses, and attack characteristics.
If Cafergot is not providing reliable relief at safe doses, or if side effects are limiting, discuss a step-therapy plan with your clinician, potentially combining a non-vasoconstrictive agent or revisiting preventive strategies to reduce attack frequency.
Individual factors affect risk-benefit decisions for Cafergot.
Maximize safety by preparing for your consultation:
In the United States, Cafergot (ergotamine tartrate and caffeine) is a prescription-only medication. Federal and state laws require that it be dispensed by a licensed pharmacy pursuant to a valid prescription issued by a licensed clinician after an appropriate evaluation. Responsible online and brick-and-mortar pharmacies will verify prescriptions, screen for contraindications and drug interactions, and provide pharmacist counseling.
HealthSouth Rehabilitation Hospital of Montgomery supports a legal and structured pathway for patients who need Cafergot but do not have a pre-existing paper prescription. Through compliant telehealth or in-person evaluation, a licensed independent prescriber can assess your medical history, review your medications, and determine if Cafergot is appropriate. When clinically indicated, the prescriber can issue an electronic prescription to a licensed U.S. pharmacy for dispensing. If Cafergot is not appropriate, the clinician will recommend safer alternatives tailored to your health profile.
Key points of the policy:
If you are considering Cafergot, start with a clinician-guided evaluation. This ensures you receive the right treatment at the right time, through legitimate pharmacy channels that prioritize your safety and comply with U.S. prescription law.
Cafergot combines ergotamine (a potent vasoconstrictor) and caffeine (which enhances absorption and vasoconstriction) to abort migraine attacks by narrowing dilated cranial blood vessels and inhibiting neurogenic inflammation when taken early in an attack.
It is for the acute treatment of migraine with or without aura; it is not for prevention and is not appropriate for tension headaches, cluster headaches (except in select specialist-directed cases), or any “everyday” headache.
Avoid if you have coronary artery disease, stroke/TIA history, peripheral vascular disease, uncontrolled hypertension, severe kidney or liver disease, sepsis, hemiplegic or brainstem (basilar) migraine, are pregnant or breastfeeding, or if you use strong CYP3A4 inhibitors; your clinician should screen you for vascular risk.
At the first sign of migraine, many labels advise 2 tablets initially, then 1 tablet every 30 minutes as needed, up to 6 tablets per attack and no more than 10 tablets per week; follow your prescriber’s instructions and never exceed recommended limits.
When taken at the earliest migraine symptoms, some people feel relief within 30–60 minutes; the earlier in the attack you take it (as soon as you’re sure it’s a migraine), the better it tends to work.
Nausea, vomiting, abdominal pain, dizziness, flushing or cold extremities, tingling in fingers or toes, muscle aches, and increased heart rate; taking an anti-nausea medicine as prescribed can help.
Chest pain, shortness of breath, severe or new numbness/tingling, pale or blue fingers or toes, severe leg pain, weakness on one side, slurred speech, severe abdominal pain, or very high blood pressure—these could signal dangerous vasospasm or ischemia.
Yes; using ergotamines on more than about 10 days per month can cause rebound headaches and reduce effectiveness; discuss a limit and a prevention plan with your clinician.
No; do not use within 24 hours of a triptan (or another ergot) because the combined vasoconstriction can be dangerous.
Strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat, clarithromycin, erythromycin, ketoconazole, itraconazole, voriconazole, grapefruit products) can cause ergot toxicity; other cautions include beta-blockers, nicotine, vasoconstrictors, some antidepressants, and linezolid—always provide a full medication list to your clinician.
Caution is advised; because ergotamine constricts blood vessels, people with cardiovascular risk need thorough evaluation or alternative therapies.
Often yes; clinicians commonly pair Cafergot with metoclopramide or prochlorperazine to reduce nausea and improve absorption, if appropriate for you.
No; it is only for acute treatment and should not be taken daily or on a schedule.
Keep tablets tightly closed at room temperature away from heat and moisture, and out of reach of children; check expiration dates and local storage instructions for your specific product.
Availability varies by country and manufacturer; some regions have generics or suppositories, others have limited or no supply—ask your pharmacist about local options.
It’s best to avoid alcohol near dosing; alcohol can worsen migraine, increase nausea and dizziness, and may raise blood pressure—if you drank, wait until you feel sober and hydrate, and consult your clinician about safer options.
No; ergotamine can reduce uterine blood flow and stimulate uterine contractions, risking fetal harm and pregnancy loss; it is contraindicated in pregnancy.
No; ergotamine passes into breast milk, can cause serious adverse effects in infants, and suppresses lactation; it is contraindicated during breastfeeding.
Tell your surgical team; because of vasoconstriction and interaction potential with anesthetic vasopressors, your clinician may ask you to stop several days before elective surgery and will advise when it’s safe to restart.
It is contraindicated in uncontrolled or severe hypertension; even with controlled blood pressure, careful monitoring is needed—many clinicians prefer alternatives in hypertensive patients.
Severe hepatic or renal impairment is a contraindication; reduced clearance increases toxicity risk—your clinician will usually choose a different acute migraine therapy.
Yes; nicotine adds vasoconstriction and increases risk of ischemic complications—avoid tobacco and nicotine products while using ergotamine.
It can cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.
Both are ergot derivatives; DHE often causes less peripheral vasoconstriction than ergotamine and may be better tolerated, especially as nasal or injectable forms used in clinics, but both share vascular risks and should not be combined or used with triptans within 24 hours.
Cafergot adds caffeine to ergotamine to enhance absorption and efficacy; the caffeine component can speed onset for some, but also may increase jitteriness or insomnia compared with ergotamine alone.
Triptans like sumatriptan generally have a more favorable safety profile and are first-line for many patients; some individuals respond better to Cafergot, especially if taken very early, but ergotamines have more interactions and contraindications.
Rizatriptan tends to have faster onset and better tolerability, with fewer serious vascular risks vs ergotamine; Cafergot may be considered if triptans are ineffective or contraindicated, under specialist guidance and with strict limits.
These triptans are effective acute options with well-characterized dosing and safety; Cafergot can be effective but requires more caution for vascular disease, drug interactions, and dosing limits.
DHE nasal can be useful when nausea limits oral intake and may have fewer peripheral ischemic effects than ergotamine; choice depends on your vascular risk, prior response, and access—both require avoidance with CYP3A4 inhibitors and triptans.
Lasmiditan does not cause vasoconstriction and may be safer in patients with cardiovascular disease, but it has CNS side effects and a driving restriction post-dose; Cafergot is contraindicated in many cardiovascular conditions.
Ubrogepant blocks CGRP pathways without vasoconstriction and has fewer cardiovascular contraindications; Cafergot works via vasoconstriction with more interaction and safety limits, but may help some who respond poorly to newer agents.
Rimegepant offers oral dosing, no vasoconstriction, and fewer drug–drug issues; Cafergot can be effective if taken early, but safety concerns limit its use—head-to-head data are limited, so individual response guides choice.
NSAIDs are often first-line for mild to moderate attacks and have a broader safety margin; Cafergot may be reserved for moderate to severe migraines unresponsive to NSAIDs, with careful monitoring for adverse effects.
Both contain caffeine, but Cafergot’s ergotamine provides strong vasoconstriction; OTC combinations can help milder attacks with fewer serious risks, while Cafergot is stronger but carries significant contraindications and interaction concerns.
Emergency department protocols often use IV metoclopramide plus diphenhydramine (± ketorolac) to treat acute migraine without vasoconstriction; Cafergot is an outpatient abortive option but is not typically used in the ER due to safety and interaction considerations.